Combining DNA damage response inhibition with a targeted therapy for aggressive breast cancer
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11005219
This study is looking for better and safer treatments for triple-negative breast cancer by testing a new combination of medicines to see if they can work together to help patients feel better with fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11005219 on ClinicalTrials.gov |
What this research studies
This research aims to develop more effective and less toxic treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The team is investigating the combination of Sacituzumab Govitecan, an antibody-drug conjugate, with a PARP inhibitor to enhance treatment efficacy. By using a sequential dosing schedule, they hope to minimize side effects while improving patient outcomes. The research includes a clinical trial to test this combination therapy in patients with metastatic TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic triple-negative breast cancer who have not responded adequately to existing therapies.
Not a fit: Patients with non-metastatic breast cancer or those with other subtypes of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results with antibody-drug conjugates and PARP inhibitors in similar contexts, indicating potential for success in this novel combination approach.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ELLISEN, LEIF W — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: ELLISEN, LEIF W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Breast Cancer Cell, Breast Cancer Patient